XOMA Royalty (XOMA) Share-based Compensation Growth (1y) (2011 - 2026)
XOMA Royalty (XOMA) Share-based Compensation Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,561.01 Bn | 66,560.72 Bn | - | 118.32% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - | - |
| 4 | BeOne Medicines | 469.79 Bn | 465.00 Bn | 1.35 Bn | -40.86% |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn | 0.18% |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.30 Bn | 3.31 Bn | 5,886.05% |
| 7 | Belite Bio | 62.62 Bn | 62.62 Bn | - | - |
| 8 | Argenx Se | 56.18 Bn | 50.99 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - | 483.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 483.33% |
| Dec 31, 2025 | -130.09% |
| Jun 30, 2025 | -73.98% |
| Mar 31, 2025 | -82.01% |
| Dec 31, 2024 | 197.58% |
| Sep 30, 2024 | -4.67% |
| Jun 30, 2024 | 24.36% |
| Mar 31, 2024 | 984.55% |
| Dec 31, 2023 | 316.78% |
| Sep 30, 2023 | 237.10% |
| Jun 30, 2023 | 158.42% |
| Mar 31, 2023 | 44.71% |
| Dec 31, 2022 | -13,677.78% |
| Sep 30, 2022 | 3.47% |
| Jun 30, 2022 | 8.98% |
| Mar 31, 2022 | -5.56% |
| Dec 31, 2021 | 101.03% |
| Sep 30, 2021 | 10.03% |
| Jun 30, 2021 | -0.65% |
| Mar 31, 2021 | 2.27% |